A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R CHOP) in Subjects ≤70 Years with Previously Untreated Non-Germinal Center Diffuse Large B Cell Lymphoma

This study is being done to understand whether patients with a type of DLBCL known as non-germinal center diffuse large B-cell lymphoma (non-GCB DLBCL) will benefit from the addition of acalabrutinib to standard R-CHOP versus R-CHOP alone, based on the biochemical or genetic profile of the lymphoma cells and the way that the disease is responding to the treatment.